Loading...
OTCM
BIOCQ
Market cap0kUSD
Mar 11, Last price  
0.00USD
1D
0.00%
1Q
0.00%
IPO
-100.00%
Name

Biocept Inc

Chart & Performance

D1W1MN
P/E
P/S
0.00
EPS
Div Yield, %
Shrs. gr., 5y
460.86%
Rev. gr., 5y
38.53%
Revenues
26m
-57.78%
1,052109,289134,245133,415609,9093,223,0965,068,6633,250,2985,528,56627,461,39861,249,00025,858,000
Net income
-32m
L+1,036.23%
-13,629,286-12,259,526-9,233,183-15,866,046-16,949,526-18,399,322-21,613,737-24,571,601-24,614,709-17,042,320-2,824,000-32,087,000
CFO
-13m
L
-10,984,373-8,607,016-6,202,363-14,605,046-15,154,841-15,697,058-19,650,726-22,355,218-23,049,261-19,787,1003,690,000-13,289,000

Profile

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
IPO date
Feb 05, 2014
Employees
50
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
25,858
-57.78%
Cost of revenue
57,841
Unusual Expense (Income)
NOPBT
(31,983)
NOPBT Margin
Operating Taxes
(125)
Tax Rate
NOPAT
(31,858)
Net income
(32,087)
1,036.23%
Dividends
Dividend yield
Proceeds from repurchase of equity
240
BB yield
Debt
Debt current
1,734
Long-term debt
22,367
Deferred revenue
Other long-term liabilities
6,132
Net debt
11,204
Cash flow
Cash from operating activities
(13,289)
CAPEX
(807)
Cash from investing activities
(807)
Cash from financing activities
(1,871)
FCF
(25,169)
Balance
Cash
12,897
Long term investments
Excess cash
11,604
Stockholders' equity
(298,436)
Invested Capital
325,537
ROIC
ROCE
EV
Common stock shares outstanding
565
Price
Market cap
EV
EBITDA
(30,328)
EV/EBITDA
Interest
316
Interest/NOPBT